Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin Oft

Showing results (21-30 of 28) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 28 results.
Molecular Cancer Therapeutics|July 29, 2010
Dinaciclib (SCH 727965), a novel and potent cyclin-dependent kinase inhibitorDavid Parry, Timothy Guzi, Frances Shanahan, et al.
Investigational New Drugs|September 10, 2020
Immunologic and tumor responses of pegilodecakin with 5-FU/LV and oxaliplatin (FOLFOX) in pancreatic ductal adenocarcinoma (PDAC)J Randolph Hecht, Kyriakos P Papadopoulos, Gerald S Falchook, et al.
The Lancet. Oncology|September 30, 2019
Pegilodecakin combined with pembrolizumab or nivolumab for patients with advanced solid tumours (IVY): a multicentre, multicohort, open-label, phase 1b trialAung Naing, Deborah J Wong, Jeffrey R Infante, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 17, 2016
Safety, Antitumor Activity, and Immune Activation of Pegylated Recombinant Human Interleukin-10 (AM0010) in Patients With Advanced Solid TumorsAung Naing, Kyriakos P Papadopoulos, Karen A Autio, et al.
Science Translational Medicine|December 18, 2012
Expression of RORγt marks a pathogenic regulatory T cell subset in human colon cancerNichole R Blatner, Mary F Mulcahy, Kristen L Dennis, et al.
Cell Reports|December 20, 2025
An IL-12 partial agonist sustains intratumoral lymphocyte activation and detoxifies systemic IL-12 therapyIevgen Koliesnik, Michael Totagrande, Bhargavi Jayaraman, et al.
Cancer Cell|November 14, 2018
PEGylated IL-10 (Pegilodecakin) Induces Systemic Immune Activation, CD8<sup>+</sup> T Cell Invigoration and Polyclonal T Cell Expansion in Cancer PatientsAung Naing, Jeffrey R Infante, Kyriakos P Papadopoulos, et al.
Cancer Cell|December 17, 2011
IL-10 elicits IFNγ-dependent tumor immune surveillanceJohn B Mumm, Jan Emmerich, Xueqing Zhang, et al.
Pageof 3

Showing results (21-30 of 28) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 28 results.
Molecular Cancer Therapeutics|July 29, 2010
Dinaciclib (SCH 727965), a novel and potent cyclin-dependent kinase inhibitorDavid Parry, Timothy Guzi, Frances Shanahan, et al.
Investigational New Drugs|September 10, 2020
Immunologic and tumor responses of pegilodecakin with 5-FU/LV and oxaliplatin (FOLFOX) in pancreatic ductal adenocarcinoma (PDAC)J Randolph Hecht, Kyriakos P Papadopoulos, Gerald S Falchook, et al.
The Lancet. Oncology|September 30, 2019
Pegilodecakin combined with pembrolizumab or nivolumab for patients with advanced solid tumours (IVY): a multicentre, multicohort, open-label, phase 1b trialAung Naing, Deborah J Wong, Jeffrey R Infante, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 17, 2016
Safety, Antitumor Activity, and Immune Activation of Pegylated Recombinant Human Interleukin-10 (AM0010) in Patients With Advanced Solid TumorsAung Naing, Kyriakos P Papadopoulos, Karen A Autio, et al.
Science Translational Medicine|December 18, 2012
Expression of RORγt marks a pathogenic regulatory T cell subset in human colon cancerNichole R Blatner, Mary F Mulcahy, Kristen L Dennis, et al.
Cell Reports|December 20, 2025
An IL-12 partial agonist sustains intratumoral lymphocyte activation and detoxifies systemic IL-12 therapyIevgen Koliesnik, Michael Totagrande, Bhargavi Jayaraman, et al.
Cancer Cell|November 14, 2018
PEGylated IL-10 (Pegilodecakin) Induces Systemic Immune Activation, CD8<sup>+</sup> T Cell Invigoration and Polyclonal T Cell Expansion in Cancer PatientsAung Naing, Jeffrey R Infante, Kyriakos P Papadopoulos, et al.
Cancer Cell|December 17, 2011
IL-10 elicits IFNγ-dependent tumor immune surveillanceJohn B Mumm, Jan Emmerich, Xueqing Zhang, et al.
Pageof 3